| PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer A Cercek, M Lumish, J Sinopoli, J Weiss, J Shia, M Lamendola-Essel, ... New England Journal of Medicine 386 (25), 2363-2376, 2022 | 765 | 2022 |
| Intestinal Blautia is associated with reduced death from graft-versus-host disease RR Jenq, Y Taur, SM Devlin, DM Ponce, JD Goldberg, KF Ahr, ... Biology of Blood and Marrow Transplantation 21 (8), 1373-1383, 2015 | 735 | 2015 |
| Intestinal microbiota and relapse after hematopoietic-cell transplantation JU Peled, SM Devlin, A Staffas, M Lumish, R Khanin, ER Littmann, L Ling, ... Journal of Clinical Oncology 35 (15), 1650-1659, 2017 | 288 | 2017 |
| Chemotherapy and COVID-19 outcomes in patients with cancer J Jee, MB Foote, M Lumish, AJ Stonestrom, B Wills, V Narendra, V Avutu, ... Journal of Clinical Oncology 38 (30), 3538-3546, 2020 | 268 | 2020 |
| A comprehensive comparison of early-onset and average-onset colorectal cancers A Cercek, WK Chatila, R Yaeger, H Walch, GDS Fernandes, A Krishnan, ... JNCI: Journal of the National Cancer Institute 113 (12), 1683-1692, 2021 | 91 | 2021 |
| Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung … SD Criss, MJ Mooradian, DF Sheehan, L Zubiri, MA Lumish, JF Gainor, ... JAMA oncology 5 (3), 358-365, 2019 | 57 | 2019 |
| Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis MJ Mooradian, DY Wang, A Coromilas, M Lumish, T Chen, ... Journal for immunotherapy of cancer 8 (1), 2020 | 48 | 2020 |
| Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer EP Darnell, TJ Wang, MA Lumish, YG Hernandez-Barco, M Weniger, ... The American Journal of Surgery 221 (1), 134-140, 2021 | 28 | 2021 |
| How we treat mature B-cell neoplasms (indolent B-cell lymphomas) M Lumish, L Falchi, BS Imber, M Scordo, G von Keudell, E Joffe Journal of Hematology & Oncology 14, 1-19, 2021 | 25 | 2021 |
| Immunotherapy for the treatment of colorectal cancer MA Lumish, A Cercek Journal of surgical oncology 123 (3), 760-774, 2021 | 23 | 2021 |
| Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer. A Cercek, MA Lumish, JC Sinopoli, JA Weiss, J Shia, ZK Stadler, ... Journal of Clinical Oncology 40 (17_suppl), LBA5-LBA5, 2022 | 22 | 2022 |
| PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. MA Lumish, JL Cohen, ZK Stadler, JA Weiss, MF Lamendola-Essel, ... Journal of Clinical Oncology 40 (4_suppl), 16-16, 2022 | 17 | 2022 |
| Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer PMR Pereira, K Mandleywala, S Monette, M Lumish, KM Tully, SS Panikar, ... Nature communications 13 (1), 2526, 2022 | 13 | 2022 |
| Oncologic immunomodulatory agents in patients with cancer and COVID-19 J Jee, AJ Stonestrom, S Devlin, T Nguyentran, B Wills, V Narendra, ... Scientific Reports 11 (1), 4814, 2021 | 12 | 2021 |
| Practical considerations in diagnosing and managing early-onset GI cancers MA Lumish, A Cercek Journal of Clinical Oncology 40 (24), 2662-2680, 2022 | 10 | 2022 |
| 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016 A Lundqvist, V van Hoef, X Zhang, E Wennerberg, J Lorent, K Witt, ... Journal for immunotherapy of cancer 4, 1-106, 2016 | 10 | 2016 |
| Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using 89Zr-trastuzumab PET: a pilot study MA Lumish, SB Maron, V Paroder, JF Chou, M Capanu, S Philemond, ... Journal of Nuclear Medicine 64 (5), 724-730, 2023 | 9 | 2023 |
| A coordinated clinical center for young onset colorectal cancer R Mendelsohn, RL Palmaira, M Lumish, J Bacani, A Krishnan, J Weiss, ... The Oncologist 26 (8), 625-629, 2021 | 9 | 2021 |
| Approach to resectable gastric cancer: Evolving paradigm of neoadjuvant and adjuvant treatment MA Lumish, GY Ku Current Treatment Options in Oncology 23 (7), 1044-1058, 2022 | 7 | 2022 |
| Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer MA Lumish, H Walch, SB Maron, W Chatila, Y Kemel, A Maio, GY Ku, ... JNCI: Journal of the National Cancer Institute 116 (2), 299-308, 2024 | 5 | 2024 |
Yelena Y. Janjigian, MDMemorial Sloan Kettering Cancer CenterPotvrđena adresa e-pošte na mskcc.org
